Mannitol formulation for integrin receptor antagonist

摘要

Disclosed are pharmaceutical compositions of an integrin alphavbeta3 receptor antagonist containing mannitol as the binding agent. The compositions are prepared by wet granulation or direct compression tablet formulation. These pharmaceutical formulations are useful for inhibiting bone resorption associated with osteoporosis, metastatic bone disease, hypercalcemia of malignancy, and Paget's disease.